… A SHP2 inhibitor is unlikely to work on its own, however. FIH trials of the first SHP2
inhibitors … to the characterization of combinations with a novel SHP2 inhibitor (PF-07284892/ARRY-…

… date, four SHP2 allosteric inhibitors have entered clinical trials for the treatment of solid
tumors… This review will provide a summary of the physiological and biological functions of SHP2 …

… represents a promising anti-cancer strategy to inhibit tumor growth and induce apoptosis in
… Although a similar mechanism has not yet been reported for solid tumors, we cannot exclude …

… mutations found in leukemia and solid tumors and exhibited 20-fold increase in the basal
phosphatase activity 6 , 34 . NS is an autosomal dominant genetic disease. Germline mutations …

… with on-target effects of SHP2 inhibition. The most common treatment-… of SHP2 inhibition,
as measured by change in DUSP6 expression by qPCR in paired pre- vs. on-treatment tumor …

RMC-4630 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2, a central
node regulating RAS signaling. Consistent with preclinical observations, initial data from a …

… of SHP2 expression and function in different solid tumor entities, … of clinical trials with allosteric
SHP2-inhibitors we discuss the … protein tyrosine phosphatase for treatment of solid tumors. …

… solid tumor malignancies. One recent study demonstrates that combined pharmacologic
inhibition of SHP2 … NF1-deficient malignant peripheral nerve sheath tumors (MPNST). This article…

… Our interests in targeting SHP2 were two-fold: 1) to create a SHP2 inhibitor … SHP2 inhibition
in different cancer contexts, including in combination with other signaling pathway inhibitors; …

… effect of the SHP2 inhibitor on T cells in vivo, and further, the impact of SHP2 inhibition on
the … The potential for SHP2 inhibitors to provide therapeutic benefit in solid tumors bearing …